Nonfunctioning XXXX : Invasiveness and recurrence.

@entity1 @entity227 @entity894 @entity5 @entity2894 @entity2124 @entity51 @entity977
BACKGROUND: We report our surgical series of 35 @entity1 with giant nonfunctioning @entity977 (GNFPA). We analyzed the rule of Ki-67 antigen expression in predicting recurrence. METHODS: Thirty-five @entity1 were operated between 2000 and 2010. Suprassellar extension of the @entity5 were classified according to Hardy and Mohr based on magnetic resonance (MR) studies. Pituitary endocrine function and MR scans were assessed preoperatively and at 1, 6, and 12 months postoperatively. Immunohistochemical studies were based in regard to the expression of the proliferative Ki-67 index and the hormonal receptor for luteinizing hormone, follicle stimulating hormone, @entity2124 , thyroid stimulating hormone, adrenocorticotropic hormone, and prolactin. Tumors specimens were obtained from 35 @entity1 with GNFPA. Endoscopic transsphenoidal surgery was the approach of choice. RESULTS: Thirty-five @entity1 were submitted to 49 surgeries, 44 (89.8%) were transsphenoidal and 5 (10.2%) were transcranial. The most frequent preoperative complaints were @entity227 and @entity227 in 25 (71.2%) and 23 (65.7%) cases, respectively. Improvement of visual acuitiy and @entity227 after surgery was seen in 20 (80%) and 17 (73.9%) @entity1 , respectively. @entity51 were encountered in 20 @entity1 (57.1%). After surgery, 18 @entity1 (51.4%) required hormonal replacement. Three @entity1 had @entity227 related to @entity2894 and recovered after surgery. The Ki-67 @entity894 ( @entity894 ) ranged from <1% to 4.8%. The rate of recurrence in @entity5 with Ki-67 <3% was 7.7% (2 @entity1 ), Ki-67 >3% was present in 5 @entity1 and the recurrence committed 3 @entity1 . CONCLUSION: In our series, regardless the improvement of visual function and compressing symptoms, 5 @entity1 with expression of Ki-67 @entity894 more than 3% experienced a recurrence.
